<s id="wsj_1069.1"> 35
1 	 0 	 N/N 	 1 	 Inc. Genentech
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Inc. said
4 	 3 	 N/N 	 1 	 profit third-quarter
4 	 5 	 S[adj]\NP 	 1 	 profit more <XB>
4 	 7 	 S[dcl]\NP 	 1 	 profit doubled
5 	 6 	 ((S\NP)/(S\NP))\(S[adj]\NP) 	 3 	 more than
7 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 doubled said
7 	 6 	 ((S\NP)/(S\NP))\(S[adj]\NP) 	 2 	 doubled than
7 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 doubled to
7 	 19 	 ((S\NP)\(S\NP))/NP 	 2 	 doubled from
9 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
11 	 9 	 N/N[num] 	 1 	 million $
11 	 10 	 N/N 	 1 	 million 11.4
15 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 cents to
15 	 14 	 N/N 	 1 	 cents 13
15 	 16 	 (NP\NP)/N 	 1 	 cents a
17 	 16 	 (NP\NP)/N 	 2 	 share a
24 	 19 	 ((S\NP)\(S\NP))/NP 	 3 	 performance from
24 	 20 	 NP[nb]/N 	 1 	 performance a
24 	 21 	 N/N 	 1 	 performance depressed
24 	 22 	 N/N 	 1 	 performance 1988
24 	 23 	 N/N 	 1 	 performance third-quarter
24 	 25 	 (NP\NP)/NP 	 1 	 performance of
26 	 25 	 (NP\NP)/NP 	 2 	 $ of
28 	 26 	 N/N[num] 	 1 	 million $
28 	 27 	 N/N 	 1 	 million 5.3
32 	 25 	 (NP\NP)/NP 	 2 	 cents of
32 	 31 	 N/N 	 1 	 cents six
32 	 33 	 (NP\NP)/N 	 1 	 cents a
34 	 33 	 (NP\NP)/N 	 2 	 share a
<\s>
<s id="wsj_1069.2"> 12
0 	 1 	 S[dcl]\NP 	 1 	 Revenue rose
1 	 3 	 (S\NP)\(S\NP) 	 2 	 rose %
1 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
1 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 rose from
3 	 2 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 23
5 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
7 	 5 	 N/N[num] 	 1 	 million $
7 	 6 	 N/N 	 1 	 million 100
9 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
11 	 9 	 N/N[num] 	 1 	 million $
11 	 10 	 N/N 	 1 	 million 81.6
<\s>
<s id="wsj_1069.3"> 17
2 	 0 	 N/N 	 1 	 sales Net
2 	 1 	 N/N 	 1 	 sales product
2 	 3 	 (S[dcl]\NP)/PP 	 1 	 sales accounted
3 	 9 	 ((S\NP)\(S\NP))/PP 	 2 	 accounted up
4 	 3 	 (S[dcl]\NP)/PP 	 2 	 for accounted
5 	 4 	 PP/NP 	 1 	 $ for
7 	 5 	 N/N[num] 	 1 	 million $
7 	 6 	 N/N 	 1 	 million 76
10 	 9 	 ((S\NP)\(S\NP))/PP 	 3 	 from up
10 	 16 	 (PP\PP)\NP 	 1 	 from earlier
11 	 10 	 PP/NP 	 1 	 $ from
13 	 11 	 N/N[num] 	 1 	 million $
13 	 12 	 N/N 	 1 	 million 57.5
15 	 14 	 NP[nb]/N 	 1 	 year a
15 	 16 	 (PP\PP)\NP 	 2 	 year earlier
<\s>
<s id="wsj_1069.4"> 30
0 	 1 	 (NP\NP)/NP 	 1 	 Sales of
0 	 6 	 (S[dcl]\NP)/NP 	 1 	 Sales were
5 	 1 	 (NP\NP)/NP 	 2 	 TPA of
5 	 2 	 NP[nb]/N 	 1 	 TPA the
5 	 3 	 N/N 	 1 	 TPA heart
5 	 4 	 N/N 	 1 	 TPA drug
7 	 6 	 (S[dcl]\NP)/NP 	 2 	 $ were
7 	 11 	 S[adj]\NP 	 1 	 $ better <XB>
9 	 7 	 N/N[num] 	 1 	 million $
9 	 8 	 N/N 	 1 	 million 43.6
11 	 12 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 2 	 better than
14 	 13 	 N/N 	 1 	 year last
14 	 15 	 (NP[nb]/N)\NP 	 2 	 year 's
18 	 12 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 3 	 period than
18 	 15 	 (NP[nb]/N)\NP 	 1 	 period 's
18 	 16 	 N/N 	 1 	 period depressed
18 	 17 	 N/N 	 1 	 period third
18 	 19 	 (NP\NP)/S[dcl] 	 1 	 period when
21 	 20 	 NP[nb]/N 	 1 	 company the
21 	 22 	 (S[dcl]\NP)/NP 	 1 	 company sold
22 	 19 	 (NP\NP)/S[dcl] 	 2 	 sold when
24 	 22 	 (S[dcl]\NP)/NP 	 2 	 $ sold
24 	 23 	 N/N 	 1 	 $ just
24 	 27 	 (NP\NP)/NP 	 1 	 $ of
26 	 24 	 N/N[num] 	 1 	 million $
26 	 25 	 N/N 	 1 	 million 29.1
29 	 27 	 (NP\NP)/NP 	 2 	 drug of
29 	 28 	 NP[nb]/N 	 1 	 drug the
<\s>
<s id="wsj_1069.5"> 22
2 	 1 	 N/N 	 1 	 sales TPA
2 	 3 	 S[dcl]\NP 	 1 	 sales fell
2 	 20 	 (S[ng]\NP)/NP 	 1 	 sales cooling <XB>
3 	 0 	 S/S 	 1 	 fell But
3 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 fell below
5 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 levels below
5 	 6 	 (NP\NP)/NP 	 1 	 levels for
8 	 7 	 NP[nb]/N 	 1 	 year this
8 	 9 	 (NP[nb]/N)\NP 	 2 	 year 's
14 	 6 	 (NP\NP)/NP 	 2 	 sales for
14 	 9 	 (NP[nb]/N)\NP 	 1 	 sales 's
14 	 10 	 N/N 	 1 	 sales first <XU>
14 	 12 	 N/N 	 1 	 sales second
14 	 13 	 N/N 	 1 	 sales quarter
14 	 15 	 (NP\NP)/NP 	 1 	 sales of
16 	 15 	 (NP\NP)/NP 	 2 	 $ of
18 	 16 	 N/N[num] 	 1 	 million $
18 	 17 	 N/N 	 1 	 million 48
21 	 20 	 (S[ng]\NP)/NP 	 2 	 investors cooling
<\s>
<s id="wsj_1069.6"> 17
1 	 0 	 N/N 	 1 	 stock Genentech
1 	 2 	 S[dcl]\NP 	 1 	 stock fell
2 	 4 	 (S\NP)\(S\NP) 	 2 	 fell cents
2 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 fell in
2 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 fell to
4 	 3 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 cents 12.5
6 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 trading in
6 	 7 	 NP\NP 	 1 	 trading yesterday
6 	 8 	 (NP\NP)/NP 	 1 	 trading on
13 	 8 	 (NP\NP)/NP 	 2 	 Exchange on
13 	 9 	 NP[nb]/N 	 1 	 Exchange the
13 	 10 	 N/N 	 1 	 Exchange New
13 	 11 	 N/N 	 1 	 Exchange York
13 	 12 	 N/N 	 1 	 Exchange Stock
15 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
16 	 15 	 N/N[num] 	 1 	 20.125 $
<\s>
<s id="wsj_1069.7"> 31
3 	 0 	 (S/S)/NP 	 2 	 months In
3 	 1 	 NP[nb]/N 	 1 	 months the
3 	 2 	 N/N 	 1 	 months nine
6 	 5 	 N/N 	 1 	 income net
6 	 7 	 S[dcl]\NP 	 1 	 income slid
7 	 0 	 (S/S)/NP 	 1 	 slid In
7 	 9 	 (S\NP)\(S\NP) 	 2 	 slid %
7 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 slid to
7 	 21 	 ((S\NP)\(S\NP))/NP 	 2 	 slid from
9 	 8 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 21
11 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
13 	 11 	 N/N[num] 	 1 	 million $
13 	 12 	 N/N 	 1 	 million 28.4
17 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 cents to
17 	 16 	 N/N 	 1 	 cents 33
17 	 18 	 (NP\NP)/N 	 1 	 cents a
19 	 18 	 (NP\NP)/N 	 2 	 share a
22 	 21 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
24 	 22 	 N/N[num] 	 1 	 million $
24 	 23 	 N/N 	 1 	 million 36
28 	 21 	 ((S\NP)\(S\NP))/NP 	 3 	 cents from
28 	 27 	 N/N 	 1 	 cents 42
28 	 29 	 (NP\NP)/N 	 1 	 cents a
30 	 29 	 (NP\NP)/N 	 2 	 share a
<\s>
<s id="wsj_1069.8"> 12
0 	 1 	 S[dcl]\NP 	 1 	 Revenues climbed
1 	 3 	 (S\NP)\(S\NP) 	 2 	 climbed %
1 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 climbed to
1 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 climbed from
3 	 2 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 18
5 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
7 	 5 	 N/N[num] 	 1 	 million $
7 	 6 	 N/N 	 1 	 million 289
9 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
11 	 9 	 N/N[num] 	 1 	 million $
11 	 10 	 N/N 	 1 	 million 245.3
<\s>
<s id="wsj_1069.9"> 27
0 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 We continue
0 	 3 	 (S[b]\NP)/PP 	 1 	 We be <XB>
1 	 19 	 (S[dcl]\S[dcl])/NP 	 1 	 continue said
2 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to continue
3 	 2 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
3 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 be on
5 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 target on
6 	 3 	 (S[b]\NP)/PP 	 2 	 for be
8 	 6 	 PP/(S[ng]\NP) 	 1 	 increasing for
8 	 16 	 ((S\NP)\(S\NP))/N 	 2 	 increasing this
10 	 8 	 ((S[ng]\NP)/NP)/NP 	 3 	 sales increasing
10 	 9 	 N/N 	 1 	 sales TPA
12 	 8 	 ((S[ng]\NP)/NP)/NP 	 2 	 % increasing
12 	 11 	 N/N 	 1 	 % 20
12 	 13 	 (NP\NP)/NP 	 1 	 % to
15 	 13 	 (NP\NP)/NP 	 2 	 % to
15 	 14 	 N/N 	 1 	 % 25
17 	 16 	 ((S\NP)\(S\NP))/N 	 3 	 year this
26 	 19 	 (S[dcl]\S[dcl])/NP 	 2 	 Swanson said
26 	 20 	 N/N 	 1 	 Swanson founder
26 	 22 	 N/N 	 1 	 Swanson Chief
26 	 23 	 N/N 	 1 	 Swanson Executive
26 	 24 	 N/N 	 1 	 Swanson Officer
26 	 25 	 N/N 	 1 	 Swanson Robert
<\s>
<s id="wsj_1069.10"> 8
2 	 1 	 NP[nb]/N 	 1 	 analysts some
2 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 analysts remain
2 	 4 	 (S[adj]\NP)/PP 	 1 	 analysts sour <XB>
3 	 0 	 S/S 	 1 	 remain But
4 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 sour remain
5 	 4 	 (S[adj]\NP)/PP 	 2 	 on sour
7 	 5 	 PP/NP 	 1 	 company on
7 	 6 	 NP[nb]/N 	 1 	 company the
<\s>
<s id="wsj_1069.11"> 7
1 	 0 	 N/N 	 1 	 sales TPA
1 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 sales are
1 	 3 	 S[adj]\NP 	 1 	 sales down <XB>
2 	 4 	 (S\NP)\(S\NP) 	 2 	 are quarter
3 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 down are
4 	 5 	 (((S\NP)\(S\NP))\((S\NP)\(S\NP)))/NP 	 3 	 quarter to
6 	 5 	 (((S\NP)\(S\NP))\((S\NP)\(S\NP)))/NP 	 4 	 quarter to
<\s>
<s id="wsj_1069.12"> 9
0 	 1 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 Expenses are
0 	 2 	 S[adj]\NP 	 1 	 Expenses flat <XB>
2 	 1 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 flat are
4 	 5 	 (S[dcl]\NP)/NP 	 1 	 that 's
8 	 5 	 (S[dcl]\NP)/NP 	 2 	 sign 's
8 	 6 	 NP[nb]/N 	 1 	 sign a
8 	 7 	 N/N 	 1 	 sign good
<\s>
<s id="wsj_1069.13"> 12
0 	 1 	 (S[dcl]\NP[thr])/NP 	 1 	 There 's
3 	 1 	 (S[dcl]\NP[thr])/NP 	 2 	 revenue 's
3 	 2 	 N/N 	 1 	 revenue contract
3 	 4 	 (NP\NP)/NP 	 1 	 revenue from
11 	 4 	 (NP\NP)/NP 	 2 	 partnerships from
11 	 6 	 N/N 	 1 	 partnerships limited
11 	 7 	 N/N 	 1 	 partnerships research
11 	 9 	 N/N 	 1 	 partnerships development
<\s>
<s id="wsj_1069.14"> 21
1 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 I think
3 	 0 	 S/S 	 1 	 think But
3 	 2 	 (S\NP)/(S\NP) 	 2 	 think still
3 	 9 	 (S[dcl]\S[dcl])/NP 	 1 	 think said
5 	 4 	 NP[nb]/N 	 1 	 fundamentals the
5 	 6 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 fundamentals are
5 	 7 	 S[adj]\NP 	 1 	 fundamentals poor <XB>
6 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 are think
7 	 6 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 poor are
11 	 9 	 (S[dcl]\S[dcl])/NP 	 2 	 Gilbert said
11 	 10 	 N/N 	 1 	 Gilbert Denise
14 	 9 	 (S[dcl]\S[dcl])/NP 	 2 	 analyst said
14 	 13 	 NP[nb]/N 	 1 	 analyst an
14 	 15 	 (NP\NP)/NP 	 1 	 analyst with
17 	 15 	 (NP\NP)/NP 	 2 	 Securities with
17 	 16 	 N/N 	 1 	 Securities Montgomery
17 	 18 	 (NP\NP)/NP 	 1 	 Securities in
20 	 18 	 (NP\NP)/NP 	 2 	 Francisco in
20 	 19 	 N/N 	 1 	 Francisco San
<\s>
<s id="wsj_1069.15"> 22
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Genentech faces
2 	 1 	 (S[dcl]\NP)/NP 	 2 	 competition faces
2 	 3 	 (NP\NP)/NP 	 1 	 competition in
2 	 7 	 (NP\NP)/NP 	 1 	 competition from
6 	 3 	 (NP\NP)/NP 	 2 	 market in
6 	 4 	 NP[nb]/N 	 1 	 market the
6 	 5 	 N/N 	 1 	 market cardiac-drug
10 	 8 	 N/N 	 1 	 PLC SmithKline
10 	 9 	 N/N 	 1 	 PLC Beecham
10 	 11 	 (NP[nb]/N)\NP 	 2 	 PLC 's
14 	 7 	 (NP\NP)/NP 	 2 	 Eminase from
14 	 11 	 (NP[nb]/N)\NP 	 1 	 Eminase 's
14 	 12 	 N/N 	 1 	 Eminase heart
14 	 13 	 N/N 	 1 	 Eminase drug
14 	 16 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 Eminase expected <XB>
14 	 18 	 (S[b]\NP)/NP 	 1 	 Eminase receive <XB>
17 	 16 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to expected
18 	 17 	 (S[to]\NP)/(S[b]\NP) 	 2 	 receive to
18 	 21 	 (S\NP)\(S\NP) 	 2 	 receive shortly
20 	 18 	 (S[b]\NP)/NP 	 2 	 approval receive
20 	 19 	 N/N 	 1 	 approval market
<\s>
<s id="wsj_1069.16"> 21
1 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 Genentech is
1 	 4 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 Genentech likely <XB>
2 	 0 	 S/S 	 1 	 is And
2 	 3 	 (S\NP)\(S\NP) 	 2 	 is n't
2 	 20 	 (S[dcl]\S[dcl])\NP 	 1 	 is added
4 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 likely is
5 	 4 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to likely
6 	 5 	 (S[to]\NP)/(S[b]\NP) 	 2 	 have to
6 	 13 	 ((S\NP)\(S\NP))/NP 	 2 	 have until
9 	 6 	 ((S[b]\NP)/(S[adj]\NP))/NP 	 3 	 products have
9 	 7 	 NP[nb]/N 	 1 	 products any
9 	 8 	 N/N 	 1 	 products new
9 	 10 	 (S[adj]\NP)/PP 	 1 	 products ready <XB>
10 	 6 	 ((S[b]\NP)/(S[adj]\NP))/NP 	 2 	 ready have
11 	 10 	 (S[adj]\NP)/PP 	 2 	 for ready
12 	 11 	 PP/NP 	 1 	 market for
15 	 14 	 (N/N)/(S[asup]\NP) 	 2 	 least at
16 	 13 	 ((S\NP)\(S\NP))/NP 	 3 	 1992 until
16 	 14 	 (N/N)/(S[asup]\NP) 	 1 	 1992 at
19 	 18 	 N/N 	 1 	 Gilbert Ms.
19 	 20 	 (S[dcl]\S[dcl])\NP 	 2 	 Gilbert added
<\s>
<s id="wsj_1069.17"> 22
1 	 0 	 NP[nb]/N 	 1 	 company The
1 	 2 	 (NP[nb]/N)\NP 	 2 	 company 's
3 	 2 	 (NP[nb]/N)\NP 	 1 	 stock 's
3 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 stock is
3 	 5 	 (S[ng]\NP)/PP 	 1 	 stock trading <XB>
4 	 21 	 (S[dcl]\S[dcl])\NP 	 1 	 is said
5 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 trading is
6 	 5 	 (S[ng]\NP)/PP 	 2 	 at trading
8 	 7 	 (NP/NP)/(NP/NP) 	 2 	 times 40
11 	 6 	 PP/NP 	 1 	 's at
11 	 8 	 NP/NP 	 1 	 's times
11 	 9 	 N/N 	 1 	 's next
11 	 10 	 N/N 	 1 	 's year
11 	 12 	 NP\NP 	 1 	 's numbers
15 	 16 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 that 's
15 	 18 	 S[adj]\NP 	 1 	 that much <XB>
16 	 21 	 (S[dcl]\S[dcl])\NP 	 1 	 's said
18 	 16 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 much 's
18 	 17 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 much too
20 	 21 	 (S[dcl]\S[dcl])\NP 	 2 	 she said
<\s>
<s id="wsj_1069.18"> 27
3 	 0 	 (S/S)/NP 	 2 	 side On
3 	 1 	 NP[nb]/N 	 1 	 side the
3 	 2 	 N/N 	 1 	 side plus
5 	 6 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 Genentech is
5 	 7 	 (S[ng]\NP)/PP 	 1 	 Genentech benefiting <XB>
6 	 0 	 (S/S)/NP 	 1 	 is On
6 	 26 	 (S[dcl]\S[dcl])\NP 	 1 	 is said
7 	 6 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 benefiting is
8 	 7 	 (S[ng]\NP)/PP 	 2 	 from benefiting
12 	 8 	 PP/NP 	 1 	 rate from
12 	 9 	 NP[nb]/N 	 1 	 rate a
12 	 10 	 N/N 	 1 	 rate lower
12 	 11 	 N/N 	 1 	 rate tax
12 	 14 	 (NP\NP)/NP 	 1 	 rate to
12 	 19 	 ((S[ng]\NP)/PP)/NP 	 1 	 rate giving <XB>
14 	 13 	 (NP\NP)/(NP\NP) 	 2 	 to due
17 	 14 	 (NP\NP)/NP 	 2 	 outlays to
17 	 15 	 NP[nb]/N 	 1 	 outlays its
17 	 16 	 N/N 	 1 	 outlays research
21 	 19 	 ((S[ng]\NP)/PP)/NP 	 3 	 boost giving
21 	 20 	 NP[nb]/N 	 1 	 boost a
22 	 19 	 ((S[ng]\NP)/PP)/NP 	 2 	 to giving
23 	 22 	 PP/NP 	 1 	 earnings to
25 	 26 	 (S[dcl]\S[dcl])\NP 	 2 	 she said
<\s>
